Pre-made Otilimab benchmark antibody ( Whole mAb, anti-CSF2 therapeutic antibody, Anti-CSF/GMCSF Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Otilimab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Otilimab (development codes MOR103 and GSK3196165) is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-415-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Otilimab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody
INN Name	Otilimab
Target	CSF2
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	5c7x:MN:HL/5d7s:HL
95-98% SI Structure	5d72:MN:HL/5d71:HL
Year Proposed	2018
Year Recommended	2019
Companies	GlaxoSmithKline;MorphoSys
Conditions Approved	na
Conditions Active	Rheumatoid arthritis
Conditions Discontinued	Inflammation;Multiple sclerosis;Osteoarthritis
Development Tech	MorphoSys HuCAL Phage Display